Evidence map›Paper›PMID 41652062›Full record

ArticleScientific reports2026

Investigating the oncogenic role of aberrant EZH2 in hepatoblastoma.

Kathryn Glaser, Erica A K DePasquale, Lara Berklite, Brian T Hickner, Priyanka Rao, Roma H Patel, Andrew A Badachhape, Somak Roy, Emily Schepers, Nikolai A Timchenko and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Kathryn GlaserDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. kathryn.glaser@cchmc.org.
Erica A K DePasqualeDivision of Gastroenterology, Cincinnati Children's Hospital Medical Center, Hepatology & Nutrition3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Lara BerkliteDivision of Pathology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Brian T HicknerPediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Priyanka RaoPediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Roma H PatelPediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Andrew A BadachhapeDepartment of Radiology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, 77030, USA.
Somak RoyDivision of Pathology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Emily SchepersDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Nikolai A TimchenkoDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
James I GellerPeckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, CA, 92123, USA.
Sarangarajan RanganathanDivision of Pathology, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Gregory M TiaoDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Bruce AronowDivision of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Takanori TakebeDivision of Gastroenterology, Cincinnati Children's Hospital Medical Center, Hepatology & Nutrition3333 Burnet Avenue, Cincinnati, OH, 45229, USA.
Sarah E WoodfieldPediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Sanjeev A VasudevanPediatric Surgical Oncology Laboratory, Divisions of Pediatric Surgery and Surgical Research, Michael E. DeBakey Department of Surgery, Dan L. Duncan Cancer Center, Texas Children's Surgical Oncology Program, Texas Children's Liver Tumor Program, Baylor College of Medicine, Houston, TX, 77030, USA.
Alexander J BondocDivision of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH, 45229, USA. alex.bondoc@cchmc.org.

Funding

High-risk hepatoblastoma dissemination control by oncogenic NRF2R01CA282467 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Sarah Elizabeth Woodfield · 2024 to 2026
$2.4M
Congressionally Directed Medical Research Programs W81XWH2110396NCI NIH HHS R01282467NCI NIH HHS R01 CA282467
6 · The paper itself

Abstract

Hepatoblastoma (HB) is the most common pediatric liver malignancy. However, its cellular origin and molecular drivers remain poorly defined. Using single-nuclear RNA sequencing (snRNA-seq), we identified a proliferative, hepatocyte-derived tumor cell population (cycling HepT) enriched for Enhancer of Zeste Homolog 2 (EZH2) expression, particularly in the aggressive embryonal subtype. Integrative genomic and transcriptomic profiling confirmed EZH2 overexpression. Disruption of the PRC2 complex was evident through mislocalization and reduced expression of SUZ12, a core component. EZH2 overexpression correlated with upregulation of mitotic regulators such as AURKB and Ki67 in human HB gene expression analysis as compared to background liver. Targeted sequencing identified variants of uncertain significance in EZH2 and SUZ12 in 11 of 11 patient tumors. Pharmacologic inhibition of EZH2 with EPZ-6438 reduced proliferation and sensitized HB cells to cisplatin through gene regulation, potentially modulating platinum accumulation both in vitro and in vivo. In summary, EZH2 promotes HB progression through epigenetic silencing and noncanonical signaling pathways. These findings support EZH2’s contribution to HB pathogenesis, therefore identifying it as a novel therapeutic target.

Indexed as

Enhancer of Zeste Homolog 2 ProteinHepatoblastomaLiver NeoplasmsAnimalsAurora Kinase BCell Line, TumorCell ProliferationCisplatinEpigenesis, GeneticFemaleGene Expression Regulation, NeoplasticHumansNeoplasm ProteinsPolycomb Repressive Complex 2Transcription FactorsAURKB protein, humanAurora Kinase BCisplatinEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanNeoplasm ProteinsPolycomb Repressive Complex 2SUZ12 protein, humanTranscription FactorsEpigeneticsEZH2HepatoblastomaMitotic regulationTherapeutic target

Identifiers

PMID41652062
PMCPMC12932671

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.